MHRA and FDA unveil major clinical trial reforms, with the UK implementing risk-based approvals and the US advancing real-time data models to accelerate drug development and patient access.
Written By: Sana Khan BPharm
Reviewed By: Pharmacally Editorial Team
Regulators in the UK and the US have introduced significant updates to clinical trial frameworks within a span of two days, underscoring a broader shift toward faster and more data-driven drug development. On 27 April 2026, the Medicines and Healthcare products Regulatory Agency (MHRA), alongside the Health Research Authority (HRA), announced a comprehensive overhaul of UK clinical trial regulations. On 27-28 April 2026, the U.S. Food and Drug Administration separately announced major steps to advance real-time clinical trials, including proof-of-concept studies and a proposed pilot program.
UK: Risk-Proportionate Reforms Now Live
The UK’s updated framework, described as the most extensive in over 20 years, is designed to accelerate trial initiation while maintaining safety standards. Key measures include faster approvals for early-stage and first-in-human trials, the introduction of “notifiable trials” to allow lower-risk studies to begin sooner, and risk-proportionate pathways such as the Route B modification process.
This pathway, piloted between October 2025 and March 2026, enabled certain protocol modifications to be processed in an average of seven days and will now be formally implemented, with approvals granted within 14 days unless concerns are raised.
The reforms also support the use of international safety data and computational modelling to inform early decisions and introduce mandatory requirements for trial registration and publication of summary results, strengthening transparency.
These changes build on recent efficiency gains, with combined regulatory and ethics reviews now averaging 41 days and overall trial set-up times reduced from 169 days to 122 days.
UK Health Innovation and Safety Minister Zubir Ahmed said the reforms are intended to improve access to new treatments and simplify the system.
MHRA Chief Executive Lawrence Tallon and HRA Chief Executive Matt Westmore emphasized streamlined approvals, maintained safety standards, and greater transparency for patients and researchers.
US: Real-Time Data Pilots Launch
In parallel, the FDA’s initiative focuses on integrating real-time data flows into clinical development, particularly in early-phase trials that are often slowed by delayed data reporting and analysis.
The agency announced the initiation of proof-of-concept real time clinical trials (RTCT) and issued a Request for Information for a pilot program expected to launch later in 2026. These trials, conducted by AstraZeneca and Amgen, enable clinical endpoints and safety signals to be transmitted directly to the FDA in real time, and the agency has already validated such data flows in at least one study.
FDA Commissioner Marty Makary stated that traditional delays in data reporting can slow regulatory decisions, while real-time access allows earlier evaluation of safety and efficacy signals.
FDA Chief AI Officer Jeremy Walsh highlighted that advances in artificial intelligence and data science support this approach and could improve both efficiency and patient safety. The agency also outlined a longer-term goal of enabling continuous clinical trials by reducing delays between development phases.
Together, these developments reflect a shared regulatory focus on reducing delays in clinical research, increasing the use of digital and real-time data, and improving patient access to new therapies, while maintaining established safety standards.
Convergence in Priorities
The reforms introduced by the Medicines and Healthcare products Regulatory Agency and the U.S. Food and Drug Administration signal a broader shift toward a more efficient and technologically integrated clinical trial ecosystem. However, UK reforms are now in force, while the FDA initiative is still moving through pilot design and stakeholder input.
UK focuses on streamlining regulatory processes through risk-based pathways and faster approvals, the US is advancing real-time data integration to reshape how evidence is generated and reviewed.
Despite these differing approaches, both regulators are converging on common priorities, including reducing delays, leveraging digital and analytical tools, and improving patient access to new therapies without compromising safety. This alignment suggests that future clinical trial frameworks are likely to become more adaptive, data-driven, and continuous in nature, setting a new global standard for adaptive, data-driven drug development.
References
Launch of clinical trial reforms – GOV.UK
FDA Announces Major Steps to Implement Real-Time Clinical Trials | FDA
About the Writer
Sana Jamil Khan is a B. Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.